BeOne Medicines Ltd.
ONCNext catalyst
Sonrotoclax
Mantle Cell Lymphoma
Get an email about ONC's next catalysts
Track BeOne Medicines (ONC) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 10 more upcoming events in our data (Phase 2 readout, Phase 3 readout).See the timeline
11 upcoming, 1 past
Sonrotoclax Phase 2 Est. Readout
Primary completion for Sonrotoclax trial (NCT06637501) in Chronic Lymphocytic Leukemia
SourceZanubrutinib Phase 2 Est. Readout (ZEBRA)
Estimated primary completion for Zanubrutinib trial (NCT06561347) in Waldenstrom Macroglobulinemia. Topline data typically follows completion by weeks to months.
SourceZanubrutinib Phase 3 Est. Readout
Estimated primary completion for Zanubrutinib trial (NCT04170283) in B-cell Malignancies. Topline data typically follows completion by weeks to months.
SourceFludarabine Phase 2 Est. Readout
Estimated primary completion for Fludarabine trial (NCT05873712) in Recurrent Transformed Chronic Lymphocytic Leukemia. Topline data typically follows completion by weeks to months.
SourceZanubrutinib Phase 2 Est. Readout
Estimated primary completion for Zanubrutinib trial (NCT03824483) in Chronic Lymphocytic Leukemia (CLL). Topline data typically follows completion by weeks to months.
SourceTacabrutideg Phase 2 Est. Readout (CaDAnCe-101)
Estimated primary completion for Tacabrutideg trial (NCT05006716) in B-cell Malignancy. Topline data typically follows completion by weeks to months.
SourceTacabrutideg Phase 2 Est. Readout
Estimated primary completion for Tacabrutideg trial (NCT05006716) in B-cell Malignancy. Topline data typically follows completion by weeks to months.
SourceBGB-B2033 Phase 2 Est. Readout
Estimated primary completion for BGB-B2033 trial (NCT06427941) in Metastatic Hepatocellular Carcinoma. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment. Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
WebsiteOxaliplatin
Advanced Unresectable Gastric Adenocarcinoma
BGB-A445
Advanced Malignancies
BAT1706
Advanced Malignancies
BGB-15025
Advanced Malignancies
LBL-007
Advanced Malignancies
Ociperlimab
Advanced Malignancies
Surzebiclimab
Advanced Malignancies
Zanubrutinib
Chronic Lymphocytic Leukemia
Leucovorin
Gastroesophageal Adenocarcinoma
Tislelizumab
Advanced Malignancies
BGB-43395
HR+/HER2- Breast Cancer
BGB-16673
B-cell Malignancy
Subcutaneous Tislelizumab
Metastatic Gastric Adenocarcinoma
Pirtobrutinib
Chronic Lymphocytic Leukemia
Sonrotoclax
Mantle Cell Lymphoma
bendamustine
Mantle Cell Lymphoma; Non-Hodgkin Lymphoma
Tacabrutideg
Chronic Lymphocytic Leukemia
Tacrolimus
Primary Membranous Nephropathy
BGB-B2033
Metastatic Hepatocellular Carcinoma
PD-1/PD-L1 inhibitors
Borderline Resectable Carcinoma
ZW25 (Zanidatamab)
HER2-amplified Biliary Tract Cancers
CAR-T Cell Therapy
Mantle Cell Lymphoma
Blinatumomab
Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
Fludarabine
Recurrent Transformed Chronic Lymphocytic Leukemia
BGB-11417
Acute Myeloid Leukemia
Dexamethasone
Relapsed/Refractory Multiple Myeloma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Oxaliplatin | Phase 3 | Advanced Unresectable Gastric Adenocarcinoma | - | - |
BGB-A445 | Phase 3 | Advanced Malignancies | - | - |
BAT1706 | Phase 3 | Advanced Malignancies | - | - |
BGB-15025 | Phase 3 | Advanced Malignancies | - | - |
LBL-007 | Phase 3 | Advanced Malignancies | - | - |
Ociperlimab | Phase 3 | Advanced Malignancies | - | - |
Surzebiclimab | Phase 3 | Advanced Malignancies | - | - |
Zanubrutinib | Phase 3 | Chronic Lymphocytic Leukemia | - | - |
Leucovorin | Phase 3 | Gastroesophageal Adenocarcinoma | - | - |
Tislelizumab | Phase 3 | Advanced Malignancies | - | - |
BGB-43395 | Phase 3 | HR+/HER2- Breast Cancer | - | - |
BGB-16673 | Phase 3 | B-cell Malignancy | - | - |
Subcutaneous Tislelizumab | Phase 3 | Metastatic Gastric Adenocarcinoma | - | - |
Pirtobrutinib | Phase 3 | Chronic Lymphocytic Leukemia | - | - |
Sonrotoclax | Phase 3 | Mantle Cell Lymphoma | - | - |
bendamustine | Phase 3 | Mantle Cell Lymphoma; Non-Hodgkin Lymphoma | - | - |
Tacabrutideg | Phase 3 | Chronic Lymphocytic Leukemia | - | - |
Tacrolimus | Phase 3 | Primary Membranous Nephropathy | - | - |
BGB-B2033 | Phase 2 | Metastatic Hepatocellular Carcinoma | - | - |
PD-1/PD-L1 inhibitors | Phase 2 | Borderline Resectable Carcinoma | - | - |
ZW25 (Zanidatamab) | Phase 2 | HER2-amplified Biliary Tract Cancers | - | - |
CAR-T Cell Therapy | Phase 2 | Mantle Cell Lymphoma | - | - |
Blinatumomab | Phase 2 | Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia | - | - |
Fludarabine | Phase 2 | Recurrent Transformed Chronic Lymphocytic Leukemia | - | - |
BGB-11417 | Phase 2 | Acute Myeloid Leukemia | - | - |
Dexamethasone | Phase 2 | Relapsed/Refractory Multiple Myeloma | - | - |
Frequently asked questions
What is in BeOne Medicines Ltd.'s drug pipeline?→
CatalystAlert tracks 26 drug candidates in BeOne Medicines Ltd.'s (ONC) pipeline across Phase 3, Phase 2. Its lead program is Zanubrutinib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is BeOne Medicines Ltd.'s next FDA catalyst?→
BeOne Medicines Ltd.'s (ONC) next tracked catalyst is a Phase 2 readout expected November 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ONC biotech catalysts?→
Add ONC to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow BeOne Medicines Ltd.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.